For information concerning this clinical site, please contact Nymox at 800-936-9669.

Annapolis, Maryland 21401

0 studies enrolling now · 4 studies all time

What they study most

BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia (BPH), LUTS, Lower Urinary Tract Symptoms (LUTS), Prostate Cancer

Studies at this site

• Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018 — Completed
• Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer — Completed
• Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) — Completed
• Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) — Completed